Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin’s Lymphoma Patients (NCT02164006)
The purpose of this study is to evaluate the safety and effectiveness of the orally available PI3K delta (PI3Kδ) inhibitor TGR-1202 (formerly known as RP5264) in combination with the anti-CD30 antibody-drug conjugate or ADC brentuximab vedotin in patients with Hodgkin lymphoma.
TGR-1202 targets the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-cell lymphocytes. To date, inhibition of PI3K delta signaling with TGR-1202 has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies.
Combination therapies aimed at enhancing the anti-tumor activity of brentuximab vedotin and reducing its side effects may offer a significant clinical impact in the treatment of relapsed/refractory Hodgkin lymphoma.
This trial is sponsored by TG Therapeutics. 
- Condition: Lymphoma
- Phase: I
- Estimated Enrollment: 14
- Start: June 2014
- Estimated Completion: March 2016
- Last verified: February 2016
Last Editorial review: July 16, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.